Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $201

Benzinga · 2d ago
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $192.1 to $201.